Drug Profile
CM 4612
Alternative Names: CM-4612; CM-ADHD; CM-AT; CM-PKLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator CureMark LLC
- Developer Curemark
- Class Enzymes
- Mechanism of Action Enzyme modulators; Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Autistic disorder
- Preclinical Attention-deficit hyperactivity disorder; Parkinson's disease
Most Recent Events
- 22 Feb 2023 CM 4612 is still in preclinical trials in Attention-deficit hyperactivity disorder in USA (PO) (Curemark pipeline, February 2023)
- 22 Feb 2023 CM 4612 is still in preclinical trials for Parkinson's disease in USA (unspecified route) (Curemark pipeline, February 2023)
- 28 Mar 2018 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in USA (PO, Powder)